Dr Rotblat was intending to discuss the matter of seroconversion further with Robert Christie of Armour to ascertain if he had any possible new evidence. Read more about Dr Rotblat was intending to discuss the matter of seroconversion further with Robert Christie of Armour to ascertain if he had any possible new evidence.
An internal Cutter memo recorded that although "Cutter will only sell 100% screened material" nonetheless "some Centre Directors are happy to use up their existing stock of unscreened Koate HT." Read more about An internal Cutter memo recorded that although "Cutter will only sell 100% screened material" nonetheless "some Centre Directors are happy to use up their existing stock of unscreened Koate HT."
The first batch of Cutter product, Koate HT, which was made from 100% tested plasma was shipped to the UK in January/February 1986. Read more about The first batch of Cutter product, Koate HT, which was made from 100% tested plasma was shipped to the UK in January/February 1986.
Cutter had shown a hepatitis rate from heat treated products of 20% in "virgin or near-virgin" patients in studies in Bonn and Freiburg, and Hyland had a rate of 80% in a multi-centre study conducted by Dr Pier Mannucci. Read more about Cutter had shown a hepatitis rate from heat treated products of 20% in "virgin or near-virgin" patients in studies in Bonn and Freiburg, and Hyland had a rate of 80% in a multi-centre study conducted by Dr Pier Mannucci.
The response by UK doctors to steps taken in the US was mixed. Dr Harris reported that Dr Rotblat "had been summoned to the Chief Medical Officer of the DHSS to answer questions concerning our product recall and discussions held in March concerning potential problems with Armour Factorate HT." Read more about The response by UK doctors to steps taken in the US was mixed. Dr Harris reported that Dr Rotblat "had been summoned to the Chief Medical Officer of the DHSS to answer questions concerning our product recall and discussions held in March concerning potential problems with Armour Factorate HT."
An inventory for Alpha UK showed that just under 25% of its current stocks remained non-heat-treated at the start of September 1985. Read more about An inventory for Alpha UK showed that just under 25% of its current stocks remained non-heat-treated at the start of September 1985.
An internal report of Cutter speaking of the UK sales position recorded that a small "short dated batch" of non-heat-treated concentrate was sold during the previous month. Read more about An internal report of Cutter speaking of the UK sales position recorded that a small "short dated batch" of non-heat-treated concentrate was sold during the previous month.
From mid March 1985 Cutter had taken the strategic decision to stop selling unheated stock to UK centres. Read more about From mid March 1985 Cutter had taken the strategic decision to stop selling unheated stock to UK centres.
Some treatment centres continued to use un-heat-treated product due to cost pressures. Read more about Some treatment centres continued to use un-heat-treated product due to cost pressures.
An internal sales report to Cutter showed a determination to continue to try to sell heat-treated products. Read more about An internal sales report to Cutter showed a determination to continue to try to sell heat-treated products.